Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • ArcticZymes Technologies News

    2,205 € -0,34% -0,0075 €
    22:32:25 Uhr L&S RT aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0HGR5
    ISIN: NO0010014632
    Typ: Aktie

    ArcticZymes Technologies News

    25.09.11 - Hugin
    Biotec Pharmacon and Affymetrix sign new agreement for the SAP enzyme
    Tromsø, 25 September, 2011: Biotec Pharmacon ASA, via its subsidiary ArcticZymes AS, and Affymetrix Inc. have signed a new non-​exclusive supply agreement for deliveries of ...
    10.08.11 - Hugin
    Q2-2011 presentation from Biotec Pharmacon
    Biotec Pharmacon presents today, August 10th, at 08:00, its interim report for the second quarter and the first half year 2011. Speakers: CEO Svein W. F. Lien, and managing director ...
    09.08.11 - Hugin
    Interim results Q2-2011 for Biotec Pharmacon
    Highlights: ENZYMES - ArcticZymes * Revenue affected by low deliveries of the lead product SAP to our exclusive customer and distributor Affymetrix (USB) * Good growth for the ...
    03.08.11 - Hugin
    Invitation to presentation of Biotec Pharmacon's results for Q2 2011
    Biotec Pharmacon presents it's second quarter and first half 2011 results on Wednesday 10 August. The results will be presented by CEO Svein Lien and Managing Director of ...
    14.07.11 - Hugin
    Biotec Pharmacon reports on neuroblastoma study
    Biotec Pharmacon ASA is announcing the final results from an early phase (I/II) study on combining Soluble Beta-​Glucan (SBG) with anti-​cancer antibodies in treatment of ...
    27.01.11 - Hugin
    Approved Prospectus for Subsequent Offering
    Tromsø, 27 January 2011 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY ...
    21.01.11 - Hugin
    Biotec Pharmacon receives promising interim results from animal study
    Tromsø, 21 January 2011 Biotec Pharmacon ASA has received an interim data report from the second animal study in diabetic mice. The results confirm the finding from the first ...
    21.01.11 - Hugin
    Biotec Pharmacon presenting in London
    CEO Svein W. F. Lien has presented Biotec Pharmacon at the Norwegian Healthcare Capital Market Day in London. Please find the presentation enclosed. This information is ...
    23.12.10 - Hugin
    Biotec Pharmacon successfully completed private placement
    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED ...
    01.12.10 - Hugin
    Biotec Pharmacon presenting at Nordic Health Care Conference
    CEO Svein Lien and Dr. Jan Buch Andersen present on behalf of Biotec Pharmacon at the Nordic Health Care Conference 2010 in Oslo. The Conference takes place at DnB NOR's ...
    01.12.10 - Hugin
    Financial Calendar 2011
    17 February 2011        Presentation of the fourth quarter report 2010 and the preliminary annual accounts 2010 11 May 2011                Annual General Meeting 13 May 2011                ...
    12.11.10 - Hugin
    Q3 presentation from Biotec Pharmacon
    Biotec Pharmacon presents today, November 12(th), 09:00, its interim report for the third quarter 2010. Speakers: CEO Svein W. F. Lien, and managing director Marine Biochemicals ...
    11.11.10 - Hugin
    Interim results for the third quarter 2010 for Biotec Pharmacon ASA
    HIGHLIGHTS §   Results from studies in mice confirm suspected differences in SBG performance depending on the type of product container used §   New and more robust gel ...
    20.09.10 - Hugin
    Biotec Pharmacon receives promising results from animal study of SBG which confirms initial findings announced in the Q2 Report
    Biotec Pharmacon has received a preliminary report of the results from the animal study of SBG (soluble beta glucan) in diabetic mice. The results confirm the initial findings ...
    09.08.10 - Hugin
    Interim results for the second quarter 2010 for Biotec Pharmacon ASA
    Tromsø/Oslo, 9 August, 2010 §  Initial feedback from a recently finalized animal study on diabetic mice indicates an effect of SBG (soluble beta glucan) in wounds supporting the ...
    28.05.10 - Hugin
    Patent granted in USA
    Biotec Pharmacon is pleased to report that one of the company's patent applications referring to a combination therapy for cancer treatment has been granted in the U.S. and will be ...
    10.03.10 - Hugin
    Svein Lien appointed new CEO of Biotec Pharmacon ASA
    (Oslo/Tromsø, 10 March, 2010) Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen's decision to resign after 3 years as CEO. Svein Lien will ...
    09.03.10 - Hugin
    Biotec Pharmacon presenting re-established platform at BIO-Europe
    Dr Sven Rohmann will present on behalf of Biotec Pharmacon at BIO-​Europe Spring 2010 in Barcelona. The presentation will take place at March 9, 12:30, under the ...
    26.02.10 - Hugin
    Interim results for the fourth quarter and full year 2009
    (Tromsø/Oslo, 26 February, 2010) Biotec Pharmacon ASA plans to initiate accelerated stability studies with SBG in a number of product containers, after disappointing results in ...
    22.02.10 - Hugin
    Testing SBG packaging containers after weak results from oral mucositis study
    (Oslo/Tromsø, 22 February, 2010) Biotec Pharmacon has received data showing that SBG failed to show superiority over placebo in the phase III study for oral mucositis. Newly ...

    Newssuche

    Videos

    08:40 Uhr +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »